The 2026 American Diabetes Association Scientific Sessions runs June 5-8 in New Orleans and is the year's most concentrated diabetes-and-metabolic-disease data event. Several Phase 3 readouts and pivotal preclinical presentations are scheduled across the major peptide therapeutic programs.
Confirmed peptide-relevant slate: Eli Lilly retatrutide TRIUMPH program (multiple of the seven 2026 readouts expected to land at ADA); Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal data with rodent weight-loss superiority over retatrutide (May 29 Poster 2839-LB); AstraZeneca eleglipron (formerly elecoglipron/AZD5004/ECC5004) full Phase 2b VISTA and SOLSTICE data after the April 29 topline; Innovent mazdutide Phase 3 GLORY-2 (18.55% mean weight reduction) and head-to-head DREAMS-3 vs semaglutide; and Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data after the April 28 topline of 16.6% mean weight loss.
The meeting also covers Pfizer berobenatide (MET-097i) Phase 3 VESPER program updates and earlier-stage peptide-receptor work across endocrine indications. Stories here cover trial readouts, plenary sessions, and the broader peptide-and-incretin slate at ADA. See #retatrutide, #mazdutide, and #survodutide.
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
At ADA 2026 on Sunday June 7, Innovent presented the Phase 3 GLORY-2 trial of mazdutide 9 mg in Chinese adults with obesity, presented by Leili Gao of Peking University People's Hospital. The dual GLP-1/glucagon agonist drove up to 20.1% mean weight loss and met its primary endpoint and all key secondary endpoints. The result extends China's homegrown obesity-peptide leadership, with mazdutide already approved by China's NMPA in 2025.
Innovent's DREAMS-3 Phase 3b head-to-head trial of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity was presented Sunday June 7 by Linong Ji of Peking University People's Hospital. On the composite primary endpoint, 48.0% of mazdutide-treated patients reached HbA1c under 7% plus at least 10% body weight reduction versus 21.0% on semaglutide. The readout is the first Phase 3 head-to-head defeat for semaglutide outside Lilly's tirzepatide series.
Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.
MetaVia presented three Sunday June 7 posters at ADA 2026. The Phase 1 higher-dose cohort of DA-1726, the once-weekly dual GLP-1/glucagon oxyntomodulin analog, builds on the prior 32 mg multiple-ascending-dose readout that showed strong effects on weight, glucose, and waist. The GPR119 agonist vanoglipel was presented in two combinations: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit.
Lexicon Pharmaceuticals presented two Sunday June 7 posters at ADA 2026. The pooled inTandem analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, showed consistent glycemic improvement and HbA1c reductions across key adult type 1 diabetes subgroups (M. Belinda Hardin). A separate Phase 1 study of the non-opioid pain candidate pilavapadin showed renal function did not affect its pharmacokinetics in patients with diabetic peripheral neuropathic pain (Rodica Pop-Busui).
Novo Nordisk hosted its R&D investor event in New Orleans on Sunday June 7, the same day as the CagriSema and zenagamtide readouts. The pipeline conversation centered on the combination strategy that pairs CagriSema and zenagamtide with the Wegovy injection and Wegovy pill, plus IcoSema and the FGF21 analog efruxifermin in MASH. Across 40 ADA abstracts, the company is reframing itself from a single-product GLP-1 leader to a multi-mechanism cardiometabolic pipeline.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.
STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.
ADA 2026 brought full TRIUMPH-4 results in adults with obesity and knee osteoarthritis. At the 12 mg dose, mean weight loss reached 28.7% at 68 weeks, and WOMAC pain scores dropped by an average of 4.5 points, a 75.8% reduction. The combination of substantial weight loss with a directly measured pain-and-function benefit positions retatrutide as the first obesity drug to land both endpoints in a single Phase 3.
On Saturday June 6, the Obesity Association (a division of the ADA) released the first stand-alone ADA Standards of Care in Overweight and Obesity: 34 new recommendations across seven sections, with a new pharmacologic-treatment section and a target of sustained body-weight reduction of at least 5%. The standards push obesity drugs from off-label discretion into anchored clinical-appropriateness criteria, the framework health systems and payers will use to write coverage policy.
Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.
At ADA 2026, Novo Nordisk reported full Phase 3 REIMAGINE 2 data for CagriSema (cagrilintide plus semaglutide fixed-dose combination) in 2,728 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Over 68 weeks, CagriSema 2.4 mg/2.4 mg produced superior HbA1c reduction of 1.91 percentage points and 14.2% mean weight loss, both better than the semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo comparator arms. The readout is the first head-to-head Phase 3 win for the dual amylin/GLP-1 combination over its individual components.
Boehringer Ingelheim and Zealand Pharma presented the full Phase 3 SYNCHRONIZE-1 readout for survodutide, the glucagon/GLP-1 dual agonist, at ADA 2026. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo (p<0.0001), with up to 85.1% achieving at least 5% loss. Analyst attention now turns to body composition and liver-fat substudies, with reductions driven largely by fat-tissue loss rather than lean mass.
MetaVia's three June 7 posters at ADA cover the higher-dose Part 3 cohort of its once-weekly dual GLP-1/glucagon agonist DA-1726, which previously cleared a 32 mg dose with strong weight, glucose, and waist effects in the multiple-ascending-dose study, and two combinations of its GPR119 agonist vanoglipel: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit. The company is small-cap but its readouts add depth to both the dual-agonist and GPR119 threads.
Lexicon Pharmaceuticals will present on Sunday, June 7 at ADA 2026: a pooled inTandem subgroup analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, in adults with type 1 diabetes (M. Belinda Hardin), and a Phase 1 study of the non-opioid pain candidate pilavapadin in patients with diabetic peripheral neuropathic pain across renal function levels (Rodica Pop-Busui). Lexicon's slate is the meeting's reminder that the diabetes pharmacology field extends beyond incretins.
Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.